Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research note released on Thursday morning,RTT News reports. The brokerage currently has a $7.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on VOR. HC Wainwright reiterated a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Tuesday, December 10th. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $8.86.

Vor Biopharma Trading Up 2.1 %

VOR stock opened at $0.87 on Thursday. The firm has a market cap of $59.75 million, a PE ratio of -0.53 and a beta of -0.40. The stock has a 50-day moving average price of $1.22 and a 200-day moving average price of $1.01. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VOR. Two Sigma Investments LP raised its position in shares of Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares during the period. Northern Trust Corp increased its stake in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares in the last quarter. Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma during the fourth quarter worth $102,000. RA Capital Management L.P. lifted its stake in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after buying an additional 16,897,159 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the fourth quarter valued at about $80,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.